Current Oncology, Volume 31, Issue 11
November 2024 - 68 articles
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story: Antibody drug conjugates (ADCs) are a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies with the cytotoxicity of chemotherapy agents. Currently, overall, more than 150 ADCs are in clinical trials. ADCs have been available for over a decade, but in gynecological cancers, ADCs have recently come up as a second-line treatment option. Moreover, newer techniques have been incorporated and next-generation ADCs have been created. Some examples include bispecific antibodies, probody drug conjugates (PDCs), immune-stimulating ADCs, degrader–antibody conjugates (DACs), and ADCs with dual chemotherapy. With so much in the pipeline, particularly with the newer techniques, this holds great promise for future. View this paper 
